Thalidomide is a synthetic drug that was initially developed as a sedative and anti-nausea medication in the late 1950s. However, it was later discovered to cause severe birth defects in infants born to mothers who had taken the drug during pregnancy. Despite this tragic outcome, thalidomide has since been found to have potential therapeutic benefits in the treatment of various diseases, including cancer, leprosy, and autoimmune disorders. This paper aims to provide a comprehensive review of thalidomide, including its method of synthesis or extraction, chemical structure and biological activity, biological effects, applications in medical, environmental, and industrial research, and future perspectives and challenges.
less than 1 mg/mL at 72° F (NTP, 1992) 545 mg/L (at 25 °C) 0.00 M In water, approximately 2X10-4 mol/L; 45-60 mg/L at 25 °C Sparingly soluble in methanol, ethanol, acetone, ethyl acetate, butyl acetate, glacial acetic acid. Very soluble in DMF. Practically insoluble in ether, chloroform, benzene. Very soluble in dioxane, pyridine 2.55e+00 g/L
Q1: How Can I Obtain a Quote for a Product I'm Interested In?
To receive a quotation, send us an inquiry about the desired product.
The quote will cover pack size options, pricing, and availability details.
If applicable, estimated lead times for custom synthesis or sourcing will be provided.
Quotations are valid for 30 days, unless specified otherwise.
Q2: What Are the Payment Terms for Ordering Products?
New customers generally require full prepayment.
NET 30 payment terms can be arranged for customers with established credit.
Contact our customer service to set up a credit account for NET 30 terms.
We accept purchase orders (POs) from universities, research institutions, and government agencies.
Q3: Which Payment Methods Are Accepted?
Preferred methods include bank transfers (ACH/wire) and credit cards.
Request a proforma invoice for bank transfer details.
For credit card payments, ask sales representatives for a secure payment link.
Checks aren't accepted as prepayment, but they can be used for post-payment on NET 30 orders.
Q4: How Do I Place and Confirm an Order?
Orders are confirmed upon receiving official order requests.
Provide full prepayment or submit purchase orders for credit account customers.
Send purchase orders to sales@EVITACHEM.com.
A confirmation email with estimated shipping date follows processing.
Q5: What's the Shipping and Delivery Process Like?
Our standard shipping partner is FedEx (Standard Overnight, 2Day, FedEx International Priority), unless otherwise agreed.
You can use your FedEx account; specify this on the purchase order or inform customer service.
Customers are responsible for customs duties and taxes on international shipments.
Q6: How Can I Get Assistance During the Ordering Process?
Reach out to our customer service representatives at sales@EVITACHEM.com.
For ongoing order updates or questions, continue using the same email.
Remember, we're here to help! Feel free to contact us for any queries or further assistance.
Quick Inquiry
Note: Kindly utilize formal channels such as professional, corporate, academic emails, etc., for inquiries. The use of personal email for inquiries is not advised.
Lenvatinib mesylate is a small molecule inhibitor that has been approved by the FDA for the treatment of various types of cancer, including thyroid cancer, renal cell carcinoma, and hepatocellular carcinoma. It is a potent inhibitor of multiple receptor tyrosine kinases, including vascular endothelial growth factor receptor (VEGFR), fibroblast growth factor receptor (FGFR), and platelet-derived growth factor receptor (PDGFR).
Semaxanib is a small molecule inhibitor of vascular endothelial growth factor receptor (VEGFR) tyrosine kinase. It was first synthesized in 1999 and has since been studied for its potential therapeutic applications in cancer treatment. Semaxanib has also been investigated for its effects on ecosystems and its use in industrial manufacturing processes.
OSI-930 is a small molecule inhibitor that targets receptor tyrosine kinases (RTKs) and has shown promising results in preclinical studies for the treatment of cancer. This paper will discuss the method of synthesis or extraction, chemical structure and biological activity, biological effects, applications, future perspectives, and challenges of OSI-930.
XL-844 is a synthetic small-molecule inhibitor of checkpoint kinases 1 and 2 (Chk1 and Chk2) with potential antineoplastic activity. XL844 binds to and inhibits Chks 1 and 2, resulting in inhibition of cell cycle arrest, progressive DNA damage, inhibition of DNA repair, and, ultimately, tumor cell apoptosis. This agent also inhibits vascular endothelial growth factor receptor 1 (VEGFR1) and vascular endothelial growth factor receptor 3 (VEGFR3), important mediators of tumor angiogenesis and lymphogenesis, respectively. In the presence of DNA damage or incomplete DNA replication, eukaryotic cells activate cell cycle checkpoints that temporarily halt the cell cycle to permit DNA repair or completion of DNA replication to take place.
ZK-304709 is a potent multi-target tumor growth inhibitor with IC50 = nanomolar inhibitory activity to cyclin-dependent kinases 1, 2, 4, 7 and 9, as well as vascular endothelial growth factor receptor tyrosine kinase 1-3 and of platelet-derived growth factor receptor beta tyrosine kinase.
Tivozanib is a small molecule tyrosine kinase inhibitor that selectively targets vascular endothelial growth factor receptors (VEGFRs). It was developed by AVEO Oncology and Astellas Pharma and was approved by the US Food and Drug Administration (FDA) in 2021 for the treatment of advanced renal cell carcinoma (RCC). Tivozanib has shown promising results in clinical trials and is being investigated for its potential use in other types of cancer and in environmental and industrial research.
Vatalanib dihydrochloride is a small molecule inhibitor that targets the vascular endothelial growth factor receptor (VEGFR) and platelet-derived growth factor receptor (PDGFR). It is used in medical research for its potential therapeutic effects in cancer treatment and in environmental research for its role in pollution management. This paper will discuss the method of synthesis or extraction, chemical structure and biological activity, biological effects, applications, future perspectives, and challenges of Vatalanib dihydrochloride.
N-(4-chloro-2-fluorophenyl)-6,7-dimethoxyquinazolin-4-amine, also known as AG-1478, is a small molecule inhibitor that targets the epidermal growth factor receptor (EGFR) tyrosine kinase. It has been extensively studied for its potential therapeutic applications in cancer treatment.